- 01GSS to acquire Microba via all-scrip merger at 0.654 GSS/share.
- 02Post-merger: Microba ~67%, GSS ~33%.
- 03No cash; ~469m new GSS shares; SID pending approvals.
Genetic Signatures (ASX: GSS) and Microba Life Sciences (ASX: MAP) have agreed on the principal commercial terms of an all-scrip merger that would create a larger Australian diagnostics group with complementary technologies, products, and international distribution networks.
Under the proposed scheme of arrangement, Genetic Signatures would acquire 100% of Microba’s issued shares and options, with Microba shareholders receiving 0.654 new Genetic Signatures shares for each Microba share held.
The transaction would result in Microba shareholders owning about 67% of the enlarged group and existing Genetic Signatures shareholders holding about 33%, while the combined business would remain listed on the ASX under the GSS ticker.
The businesses generated approximately $29.6 million in aggregate financial year 2026 revenue and reported about $30m in combined cash and term deposits at 30 June 2026.
No cash consideration or new acquisition financing is contemplated as part of the proposed transaction.
Definitive SID to Follow
Subject to finalisation, Genetic Signatures would issue approximately 469 million new shares to Microba shareholders under the proposed exchange ratio, while Microba option holders would receive equivalent Genetic Signatures options on the same 0.654 ratio.
The companies intend to execute a definitive Scheme Implementation Deed (SID) after Genetic Signatures shareholders approve proceeding with the transaction, with the merger then requiring further shareholder, regulatory and Court approvals.
The proposed combination would unite Genetic Signatures’ rapid targeted pathogen detection capabilities with Microba’s broader microbiome profiling technologies, creating a wider offering across gastrointestinal and infectious disease diagnostics.
“Bringing Microba and Genetic Signatures together would create an exciting opportunity to combine two complementary areas of diagnostic innovation—by bringing our respective technologies, expertise, and commercial capabilities together, we have the potential to build a stronger diagnostics platform and accelerate the delivery of new solutions to clinicians and patients globally,” Genetic Signatures chair Mike Aicher said.
“We believe this pro-posed combination provides a compelling foundation for long-term growth and value creation for shareholders.”
Combined Scale and Synergies
Based on the aggregated figures provided by the two businesses, the combined group would have an indicative equity value of about $51m, net assets of $60.1m at 30 June 2026, and approximately 149 employees.
Genetic Signatures brings hospital and reference laboratory relationships, international distribution partners, and existing regulatory approvals, while Microba contributes clinician networks, established operations in the UK, and pathology relationships.
Preliminary analysis has identified at least $2.5m-$3.0m in potential annualised gross cost synergies, principally from consolidating duplicated listed-company costs, overlapping corporate functions, and selected infrastructure and professional services expenditure.
“This merger creates a leader in gastrointestinal diagnostics, with broader revenue and customer bases, and a materially stronger balance sheet to meet the significant global opportunity facing the merged group,” Microba chair Pasquale Rombola said.
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.